Dr. Weickert is CEO of Pacylex Pharmaceuticals and has been developing drugs and startup companies in biotech and pharmaceuticals for 29 years. He is also Executive Chairman of Chelation Partners and has been CEO of illumiSonics, Sonescence, and SEA Medical Systems, CBO of Strategent Life Sciences, Corium, and Therashock, COO of Greenfire Bio and Ohm Oncology, VP of development at SciDose and Auspex, and Senior Program Executive or Manager at Nektar and Ligand. Michael has driven oncology product development including Phase III/NDA for Targretin for Cutaneous T-cell Lymphoma, and business planning for drug delivery of the cancer drugs Leuprolide, Paclitaxel and Irinotecan. He obtained Orphan Drug and Fast Track designations for oncology-related products in the US and EU. At startups, he raised Seed through Series C capital and established partnerships worth more than $190 Million. Prior to joining the pharmaceutical industry, he was at the National Cancer Institute at NIH. He obtained his PhD at the University of Wisconsin.